LUX-Lung 3 & 6 trials video

Topline data from LUX-Lung 3 & 6 trials

"The LUX-lung portfolio of trials, particularly in the first line setting, this is the LUX-Lung 3 and the LUX-Lung 6 trials, have now demonstrated that in patients with EGFR mutation in their lung cancer, that treatment with afatinib is superior to standard platinum doublet based chemotherapy."